Published: 2021-07-26

Comparative study of ormeloxifene and low dose oral contraceptive pill for the treatment of dysfunctional uterine bleeding in peri-menopausal age group

Maitri Shah, Chirayu Parmar, Riddhi Gor


Background: Dysfunctional uterine bleeding (DUB) is the most common menstrual disorder of women in any age group and is a diagnosis of exclusion. Medical management of menorrhagia is a difficult task as there are wide variations in the available drugs and a lot of different regimes are available. Present study evaluates efficacy and safety of ormeloxifene a selective estrogen receptor modulator (SERMs) as compared to combined oral contraceptive pills in treatment of dysfunctional uterine bleeding in perimenopausal women.

Methods: Total 60 patients meeting with our inclusion and exclusion criteria were enrolled in the study over a time period of 6 months and were further divided randomly into two groups. One group was given Ormeloxifene and the other group was treated with combined oral contraceptive pills (COCP) over a period of six months. The outcome variables noted were pictorial blood loss assessment chart (PBAC) score, Hb level and combined endometrial thickness (CET). Quantitative variables were compared using independent t test/Mann-Whitney test between the two groups and paired t Test/Wilcoxon test was used for comparison between pre and post within the group.

Results: Both ormeloxifene and COCP significantly reduce blood loss in these patients evidenced by decrease of PBAC score, rise in hemoglobin levels and decrease in CET levels. However, ormeloxifene was found to be superior to COCP in reducing the menstrual blood loss. Ormeloxifene was also tolerated better compared to COCP with fewer side effects experienced by patients.


Ormeloxifene, Perimenopausal, DUB

Full Text:



Bravender T, Emans S. Menstrual Disorders. Dysfunctional Uterine Bleeding. Pediatr Clin North Am. 1999;3(46):545-53.

Dadich SA, Soni M, Jain R. Role of ormeloxifene in medical management of dysfunctional uterine bleeding. Asian J Obs Gynae Pract. 2012;6:28-31.

Singh HO, Singh A, Dhole TN, Nain S. Biochemistry and Physiology. Open Access Effect of Ormeloxifene for Management of Dysfunctional Uterine Bleeding. Biochem Physiol. 2015;4(3):4-6.

Practice C. Efficacy of a Selective Estrogen Receptor Modulator: ‘Ormeloxifene’ in Management of Dysfunctional Uterine Bleeding. Biochem Physiol. 2010;2:207-11.

Grover S, Chhabra A, Bindu S. A Study of Ormeloxifene in Case of Dysfunctional Uterine Bleeding. Int J Med Dent Sci. 2013;2(2):162-9.

KJ J. A comparative study on the effectiveness of ormeloxifene versus norethisterone in the management of perimenopausal dysfunctional uterine bleeding. IAIM. 2015;88.

Komaram R, Palla J, Swamy Chintada G. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diagnostic Res. 2013.

Goldstein SR, Nanavati N. Selective Oestrogen Receptor Modulator Levormeloxifene in the treatment of osteoporosis. Am J Obstet Gynaecol. 2002;187(3):521.

Cardoso PM. A Comparative Study of the Efficacy of Ormeloxifene and Norethisterone in Perimenopausal Dysfunctional Uterine Bleeding and Perimenopausal Symptoms. J Dental Med Sci. 2016;15(1):57-62.

Agarwal NU, Kriplani A. Medical management of dysfunctional uterine bleeding. Int J Gynaecol Obstet. 2001;7:199-201.

Agarwal N, Singh S, Singh S, Agarwal M, Manocha P. Comparative evaluation of the efficacy and safety of ormeloxifene and norethisterone in dysfunctional uterine bleeding. Int J Reprod Contraception, Obstet Gynecol. 2013;2(2):194.

Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD. Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid, Profile Compared to Low Dose Hormone Replacement Therapy. J Clin Endocrinol Metab. 2001;86(2):755-60.

Kriplani A, Kulshrestha V, Agarwal N. Efficacy and safety of ormeloxifene in management of menorrhagia: A pilot study. J Obstet Gynaecol Res. 2009;35(4):746-52.

Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97(8):734-9.

Shravage J, Mekhala D, Bellad MB, Ganachari MS, Dhumale HA. Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding: A double-blind randomized controlled trial. J SAFOG. 2011.

Khan SA, Manzoor M, Abdullah A, Banoo A. Efficacy and Safety of Ormeloxifene in the Management of Dysfunction Uterine Bleeding. J Dent Med Sci. 2014;13(6):39-42.

Khare V, Ghosh G, Patil P, Nagar N. Ormeloxifen HCL (SERM), Oral Contraceptive Pills, DUB. Ormeloxifen HCL VS Comb oral Contracept PILL Treat DUB. 2014;3084.